{"classes":[{"categories":[{"measurements":[{"comment":"NA: The upper confidence interval for median PFS was not estimable because the number of progression or death events was insufficient to estimate the upper CI boundary at the time of analysis.","groupId":"OG000","lowerLimit":"18.2","upperLimit":"NA","value":"53.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Progression free survival is the time from tisagenlecleucel infusion to first documented disease progression or death due to any cause. PFS was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set (EAS): All the patients who received tisagenlecleucel, and had measurable disease at baseline per IRC. Non-measurable disease at baseline is defined as absence of index lesion at baseline disease evaluation (i.e. no disease at baseline).","reportingStatus":"POSTED","timeFrame":"up to 61.7 months","title":"Progression Free Survival (PFS) Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"months"}